Review



sarctrack sarcomere analysis software  (MathWorks Inc)


Bioz Verified Symbol MathWorks Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    MathWorks Inc sarctrack sarcomere analysis software
    SPEDOX-6 induces less functional toxicity than UF DOX in hiPSC-CMs (A) hiPSC-CM beat rate normalized to DMSO after 3 days of UF DOX or SPEDOX-6 treatment. See . ∗ p < 0.05 between DMSO and other groups, determined by one-way ANOVA with Tukey’s post hoc test. n = 4 independent experiments. (B) Representative field potential recordings from contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h. (C) Average spike amplitude mean and field potential duration (FPD) mean from field potential recordings of contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h, corresponding with (B). n = 9 technical replicates. Error bars represent SD. (D) Live fluorescence imaging of ACTN2-GFP hiPSC-CMs subjected to DMSO, UF DOX, or SPEDOX-6 for up to 72 h. α-actinin (green) represents a cardiomyocyte-specific protein marking the striated cardiac sarcomeres in live hiPSC-CMs. DOX (red) shows DOX intracellular accumulation. (E) <t>SarcTrack</t> dataset showing representative sarcomere displacement timegraphs of ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . (F) SarcTrack-based quantification of sarcomere displacement during the hiPSC-CM contraction cycle in ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . n = 10, 29, and 22 sarcomeres were detected for DMSO, UF DOX, and SPEDOX-6 conditions, respectively. (G) Calcium imaging timegraphs of WTC-GCaMP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. ΔF/F0 compares the change of the fluorescence intensity to the baseline fluorescence intensity before the contraction. See .
    Sarctrack Sarcomere Analysis Software, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sarctrack sarcomere analysis software/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    sarctrack sarcomere analysis software - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy"

    Article Title: Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy

    Journal: Stem Cell Reports

    doi: 10.1016/j.stemcr.2023.08.005

    SPEDOX-6 induces less functional toxicity than UF DOX in hiPSC-CMs (A) hiPSC-CM beat rate normalized to DMSO after 3 days of UF DOX or SPEDOX-6 treatment. See . ∗ p < 0.05 between DMSO and other groups, determined by one-way ANOVA with Tukey’s post hoc test. n = 4 independent experiments. (B) Representative field potential recordings from contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h. (C) Average spike amplitude mean and field potential duration (FPD) mean from field potential recordings of contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h, corresponding with (B). n = 9 technical replicates. Error bars represent SD. (D) Live fluorescence imaging of ACTN2-GFP hiPSC-CMs subjected to DMSO, UF DOX, or SPEDOX-6 for up to 72 h. α-actinin (green) represents a cardiomyocyte-specific protein marking the striated cardiac sarcomeres in live hiPSC-CMs. DOX (red) shows DOX intracellular accumulation. (E) SarcTrack dataset showing representative sarcomere displacement timegraphs of ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . (F) SarcTrack-based quantification of sarcomere displacement during the hiPSC-CM contraction cycle in ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . n = 10, 29, and 22 sarcomeres were detected for DMSO, UF DOX, and SPEDOX-6 conditions, respectively. (G) Calcium imaging timegraphs of WTC-GCaMP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. ΔF/F0 compares the change of the fluorescence intensity to the baseline fluorescence intensity before the contraction. See .
    Figure Legend Snippet: SPEDOX-6 induces less functional toxicity than UF DOX in hiPSC-CMs (A) hiPSC-CM beat rate normalized to DMSO after 3 days of UF DOX or SPEDOX-6 treatment. See . ∗ p < 0.05 between DMSO and other groups, determined by one-way ANOVA with Tukey’s post hoc test. n = 4 independent experiments. (B) Representative field potential recordings from contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h. (C) Average spike amplitude mean and field potential duration (FPD) mean from field potential recordings of contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h, corresponding with (B). n = 9 technical replicates. Error bars represent SD. (D) Live fluorescence imaging of ACTN2-GFP hiPSC-CMs subjected to DMSO, UF DOX, or SPEDOX-6 for up to 72 h. α-actinin (green) represents a cardiomyocyte-specific protein marking the striated cardiac sarcomeres in live hiPSC-CMs. DOX (red) shows DOX intracellular accumulation. (E) SarcTrack dataset showing representative sarcomere displacement timegraphs of ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . (F) SarcTrack-based quantification of sarcomere displacement during the hiPSC-CM contraction cycle in ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . n = 10, 29, and 22 sarcomeres were detected for DMSO, UF DOX, and SPEDOX-6 conditions, respectively. (G) Calcium imaging timegraphs of WTC-GCaMP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. ΔF/F0 compares the change of the fluorescence intensity to the baseline fluorescence intensity before the contraction. See .

    Techniques Used: Functional Assay, Fluorescence, Imaging



    Similar Products

    90
    MathWorks Inc sarctrack sarcomere analysis software
    SPEDOX-6 induces less functional toxicity than UF DOX in hiPSC-CMs (A) hiPSC-CM beat rate normalized to DMSO after 3 days of UF DOX or SPEDOX-6 treatment. See . ∗ p < 0.05 between DMSO and other groups, determined by one-way ANOVA with Tukey’s post hoc test. n = 4 independent experiments. (B) Representative field potential recordings from contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h. (C) Average spike amplitude mean and field potential duration (FPD) mean from field potential recordings of contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h, corresponding with (B). n = 9 technical replicates. Error bars represent SD. (D) Live fluorescence imaging of ACTN2-GFP hiPSC-CMs subjected to DMSO, UF DOX, or SPEDOX-6 for up to 72 h. α-actinin (green) represents a cardiomyocyte-specific protein marking the striated cardiac sarcomeres in live hiPSC-CMs. DOX (red) shows DOX intracellular accumulation. (E) <t>SarcTrack</t> dataset showing representative sarcomere displacement timegraphs of ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . (F) SarcTrack-based quantification of sarcomere displacement during the hiPSC-CM contraction cycle in ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . n = 10, 29, and 22 sarcomeres were detected for DMSO, UF DOX, and SPEDOX-6 conditions, respectively. (G) Calcium imaging timegraphs of WTC-GCaMP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. ΔF/F0 compares the change of the fluorescence intensity to the baseline fluorescence intensity before the contraction. See .
    Sarctrack Sarcomere Analysis Software, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sarctrack sarcomere analysis software/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    sarctrack sarcomere analysis software - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    SPEDOX-6 induces less functional toxicity than UF DOX in hiPSC-CMs (A) hiPSC-CM beat rate normalized to DMSO after 3 days of UF DOX or SPEDOX-6 treatment. See . ∗ p < 0.05 between DMSO and other groups, determined by one-way ANOVA with Tukey’s post hoc test. n = 4 independent experiments. (B) Representative field potential recordings from contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h. (C) Average spike amplitude mean and field potential duration (FPD) mean from field potential recordings of contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h, corresponding with (B). n = 9 technical replicates. Error bars represent SD. (D) Live fluorescence imaging of ACTN2-GFP hiPSC-CMs subjected to DMSO, UF DOX, or SPEDOX-6 for up to 72 h. α-actinin (green) represents a cardiomyocyte-specific protein marking the striated cardiac sarcomeres in live hiPSC-CMs. DOX (red) shows DOX intracellular accumulation. (E) SarcTrack dataset showing representative sarcomere displacement timegraphs of ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . (F) SarcTrack-based quantification of sarcomere displacement during the hiPSC-CM contraction cycle in ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . n = 10, 29, and 22 sarcomeres were detected for DMSO, UF DOX, and SPEDOX-6 conditions, respectively. (G) Calcium imaging timegraphs of WTC-GCaMP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. ΔF/F0 compares the change of the fluorescence intensity to the baseline fluorescence intensity before the contraction. See .

    Journal: Stem Cell Reports

    Article Title: Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy

    doi: 10.1016/j.stemcr.2023.08.005

    Figure Lengend Snippet: SPEDOX-6 induces less functional toxicity than UF DOX in hiPSC-CMs (A) hiPSC-CM beat rate normalized to DMSO after 3 days of UF DOX or SPEDOX-6 treatment. See . ∗ p < 0.05 between DMSO and other groups, determined by one-way ANOVA with Tukey’s post hoc test. n = 4 independent experiments. (B) Representative field potential recordings from contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h. (C) Average spike amplitude mean and field potential duration (FPD) mean from field potential recordings of contracting hiPSC-CMs in multielectrode arrays treated with DMSO, UF DOX, or SPEDOX-6 for up to 72 h, corresponding with (B). n = 9 technical replicates. Error bars represent SD. (D) Live fluorescence imaging of ACTN2-GFP hiPSC-CMs subjected to DMSO, UF DOX, or SPEDOX-6 for up to 72 h. α-actinin (green) represents a cardiomyocyte-specific protein marking the striated cardiac sarcomeres in live hiPSC-CMs. DOX (red) shows DOX intracellular accumulation. (E) SarcTrack dataset showing representative sarcomere displacement timegraphs of ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . (F) SarcTrack-based quantification of sarcomere displacement during the hiPSC-CM contraction cycle in ACTN2-GFP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. See . n = 10, 29, and 22 sarcomeres were detected for DMSO, UF DOX, and SPEDOX-6 conditions, respectively. (G) Calcium imaging timegraphs of WTC-GCaMP hiPSC-CMs treated with DMSO, UF DOX, or SPEDOX-6 for 72 h. ΔF/F0 compares the change of the fluorescence intensity to the baseline fluorescence intensity before the contraction. See .

    Article Snippet: Videos were analyzed in MATLAB R2022 using SarcTrack sarcomere analysis software, as shown previously ( ).

    Techniques: Functional Assay, Fluorescence, Imaging